A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

This study has been completed.
Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			HIV Infections
			Hepatitis C
2		Additional conditions recognized in this trial
			Acquired Immunodeficiency Syndrome
			Communicable Diseases
			Hepatitis
			Infection
3		More general conditions related to this trial
			Digestive System Diseases
			Flaviviridae Infections
			Hepatitis, Viral, Human
			Immune System Diseases
			Immunologic Deficiency Syndromes
			Lentivirus Infections
			Liver Diseases
			Retroviridae Infections
			RNA Virus Infections
			Sexually Transmitted Diseases
			Sexually Transmitted Diseases, Viral
			Slow Virus Diseases
			Virus Diseases
4		Interventions listed in this trial
			Ribavirin
			Interferon alfa-2a
			Peginterferon alfa-2a
5		Additional drug interventions recognized in this trial
			Interferon Alfa-2b
			Interferon Type I, Recombinant
			Interferon-alpha
			Interferons
6		More general drug interventions related to this trial
			Angiogenesis Inhibitors
			Angiogenesis Modulating Agents
			Anti-Infective Agents
			Antimetabolites
			Antineoplastic Agents
			Antiviral Agents
			Growth Inhibitors
			Growth Substances
			Immunologic Factors
			Molecular Mechanisms of Pharmacological Action
			Pharmacologic Actions
			Physiological Effects of Drugs
			Therapeutic Uses
7		Sponsors listed in this trial
			National Institute of Allergy and Infectious Diseases (NIAID)